



Attorney Docket No.: ChG\_00107


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Suresh C. Srivastava, Satya P. Bajpai and Kwok-Hung Sit  
Assignee of Part interest: ChemGenes Corporation  
Application Serial No.: 10/768,996  
Filed: January 30, 2004  
Title: NOVEL OLIGONUCLEOTIDES AND RELATED COMPOUNDS  
Art Unit: 1642  
Examiner: Brandon J. Fetterolf, Ph.D.

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence is included in an envelope with the United States Postal Service as Express Mail under Label No. EG 371685823 US on the date signed and addressed to:

Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Signature

Y. Anand  
(Name)

10/19/2010  
Date

**In the Specification**


Please replace the sequence listing in the above noted application with the Sequence Listing enclosed herewith.


The enclosed Sequence Listing is submitted on paper as well as on a Compact Disc. The content of the Sequence Listing in CRF is identical to the Sequence Listing submitted on paper.

No new matter is introduced by this submission.

Dated: October 19, 2010

Respectfully,

By   
Indu M. Anand  
Registration Number: 52,557  
15 Green Way  
Chelmsford, MA 01824  
(978) 250-9003/ (617) 930-5000



## Notice to Comply

Application No.  
10768996

Applicant(s)  
SRIVASTAVA ET AL.

Examiner  
Misook Yu

Art Unit  
1643

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

#### Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951  
For CRF Submission Help, call (571) 272-2510  
PatentIn Software Program Support  
Technical Assistance. 1-866-217-9197 or 703-305-3028 or 571-272-6845  
PatentIn Software is Available At [www.USPTO.gov](http://www.USPTO.gov)

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

Misook Yu  
SPE  
Art Unit: 1643

/Misook Yu/



# **Examiner-Initiated Interview Summary**

Application No.	Applicant(s)	
10/768,996	SRIVASTAVA ET AL.	
Examiner	Art Unit	
Misook Yu	1643	

## **All Participants:**

(1) Misook Yu.

(2) Indu Anand.

## **Status of Application: \_\_\_\_\_**

(3) \_\_\_\_\_

(4) \_\_\_\_\_

**Date of Interview:** 4 October 2010

**Time:** \_\_\_\_\_

## **Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

**Exhibit Shown or Demonstrated:** ☐ Yes ☐ No  
If Yes, provide a brief description:

## **Part I.**

Rejection(s) discussed:

Claims discussed:

Prior art documents discussed:

## **Part II.**

### **SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*CRF submitted on 01/31/2008 has been found to be flawed technically and has not been entered. Applicant's representative stated that applicant would file a new CRF.*

## **Part III.**

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Misook Yu/  
Supervisory Patent Examiner, Art Unit 1643

(Applicant/Applicant's Representative Signature – if appropriate)